🟢 Neurosense Therapeutics is trading 8.69% up today after HC Wainwright initiated Buy-rated coverage

Neurosense Therapeutics is trading 8.69% up now at $0.45 after HC Wainwright initiated coverage on September 3, 2026, with a Buy rating and an $8.00 price target.

• The analyst action follows the company’s August 31 announcement of a redesigned, capital-efficient PrimeC development strategy for ALS.
• XBI is up 2.75%, but analyst coverage appears to be the primary driver.